June 2020 Vol. 8 No.6

Abstract
Full text
Reprint (PDF) (155 KB)

Search Pubmed for articles by:
 

Case Report

Etanercept Induced Bullous Pemphigoid Skin Lesion in Rheumatoid Arthritis: A Case Report

Abdulsatar J. Mathkhor^1*, Jinan Q. Mohammed² and Abdulnasser H. Abdullah³

¹Rheumatologist. Rheumatology unit in Basra Teaching Hospital Basra. Iraq
²Dermatologist. Dermatology unit in Basra Teaching Hospital Basra. Iraq
³Rheumatologist, Rheumatology unit in Al sader Teaching Hospital, Basra. Iraq

*Corresponding author's E-mail: amathkhoor@yahoo.co.uk

Received: 04 June 2020  I  Accepted: 24 June 2020 I Published: 28 June 2020   I  Article ID: MRJMMS-20-098
Copyright © 2020 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0.

Abstract

Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine produced predominantly by activated macrophages, and involved in the up-regulation of inflammatory reactions, and plays a pivotal role in the pathogenesis of rheumatoid arthritis and some other autoimmune disorders. Since their introduction anti-TNF-α agents have been revolutionized the treatment of these disorders. However, some adverse events such as skin reaction, hypersensitivity, infection, reactivation of tuberculosis, and various autoimmune diseases can occur in patients using these agents. In this report, we present a female case who was diagnosed as bullous pemphigoid while receiving etanercept for treatment of rheumatoid arthritis.

Keywords: Anti-tumor necrosis factoralpha, Bullous pemphigoid, Rheumatoid arthritis